论文部分内容阅读
目的:探讨阿奇霉素治疗支原体诱发咳嗽变异性哮喘的临床疗效。方法:选取2012年6月-2014年1月我院收治的咳嗽变异性哮喘患者60例,按随机数字表法将其分成实验组30例,对照组30例,两组患者均应用常规治疗,在此基础上对照组应用糖皮质激素治疗,实验组应用阿奇霉素治疗,比较分析两组患者临床疗效。结果:实验组临床总有效率为93.3%,用力呼气流量(PEFR)为(0.62±0.30)L/s,第1秒用力呼气容积(FEV1)为(0.75±0.62),与对照组相比差异均有统计学意义(P<0.05)。结论:咳嗽变异性哮喘(支原体诱发)患者应用阿奇霉素治疗,疗效显著,值得临床推广应用。
Objective: To investigate the clinical efficacy of azithromycin in the treatment of mycoplasma-induced cough variant asthma. Methods: Sixty patients with cough variant asthma admitted in our hospital from June 2012 to January 2014 were divided into experimental group (n = 30) and control group (n = 30) according to random number table method. Both groups were treated by routine therapy, On this basis, the control group was treated with glucocorticoid, the experimental group was treated with azithromycin, and the clinical efficacy was compared between the two groups. Results: The total clinical effective rate was 93.3% in the experimental group, forced expiratory flow (PEFR) was (0.62 ± 0.30) L / s and forced expiratory volume in 1 second was (0.75 ± 0.62) The differences were statistically significant (P <0.05). Conclusion: Patients with cough variant asthma (induced by mycoplasma) are treated with azithromycin, which has a significant curative effect and is worthy of clinical application.